Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly…(LINKER-MM8) | Phase 2 / Phase 3 | withdrawn | Feb 23, 2026 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT01272609 | Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel | Phase 3 | terminated | Jan 10, 2011 | Centre Hospitalier Universitaire de Nice | Rupture du traitement | Other (stated, no rule matched) |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03216187 | Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of…(PREVENT) | Phase 3 | terminated | Jul 13, 2017 | Benno Rehberg-Klug | insufficient funding and recruitment | Enrollment / accrual |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy…(CANOPY-1) | Phase 3 | terminated | Aug 15, 2018 | Novartis Pharmaceuticals | Results of primary analysis showed addition of canakinumab to combination treatment did not improve… | Safety / toxicity |
| NCT07199413 | Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic… | Phase 1 | withdrawn | Sep 30, 2025 | Medical College of Wisconsin | Study never started. | Other (stated, no rule matched) |
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With… | — | withdrawn | Sep 16, 2016 | Centre Hospitalier Universitaire de Nice | L'investigateur est parti du CHU de Nice | Other (stated, no rule matched) |
| NCT05159388 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 16, 2021 | Servier Bio-Innovation LLC | Sponsor decision to terminate during Phase 1 | Sponsor / business decision |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple… | Phase 1 | terminated | Aug 12, 2022 | Second Affiliated Hospital of Xi'an Jiaotong University | Achieved the proof of concept | Other (stated, no rule matched) |
| NCT05789589 | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain…(ADORATION) | Phase 1 / Phase 2 | suspended | Mar 29, 2023 | Baptist Health South Florida | Funding | Funding |
| NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable… | N/A | withdrawn | Aug 22, 2025 | University of Alabama at Birmingham | Study PI is leaving UAB and no longer opening study. | Other (stated, no rule matched) |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to… | Phase 2 | terminated | Mar 19, 2019 | Mayo Clinic | slow accrual; insufficient funding to continue to accrue | Enrollment / accrual |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With… | Phase 2 / Phase 3 | terminated | Jan 6, 2021 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | Phase 1 | suspended | Jun 10, 2022 | University of Alabama at Birmingham | IRB audit | Other (stated, no rule matched) |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Phase 2 | terminated | Jul 12, 2022 | University of Washington | The trial closed early due to slow accrual. | Enrollment / accrual |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | Phase 2 / Phase 3 | terminated | Oct 28, 2022 | Wake Forest University Health Sciences | Study initially suspended following an audit and need of amendment to address deficiencies. PI… | Other (stated, no rule matched) |
| NCT05785715 | Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe… | Phase 2 | terminated | Mar 27, 2023 | AbbVie | Sponsor Decision\_Not Safety Related | Safety / toxicity |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | N/A | terminated | Jun 22, 2010 | Massachusetts General Hospital | The study was closed to enrollment due to slow accrual. | Enrollment / accrual |
| NCT02602756 | Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas(HYGROMEL) | N/A | terminated | Nov 11, 2015 | Centre Antoine Lacassagne | insufficient quality of data collection | Other (stated, no rule matched) |
| NCT02971995 | Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies(PROSTEPIRM) | N/A | terminated | Nov 23, 2016 | Lille Catholic University | Difficulties encountered in enrolling patients | Enrollment / accrual |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20… | Phase 2 | terminated | Oct 24, 2017 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT03688789 | Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy…(HemaSur) | N/A | withdrawn | Sep 28, 2018 | Rennes University Hospital | Investigator leaving the hospital | Investigator |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Phase 2 | terminated | Sep 22, 2022 | Sun Yat-sen University | The study was terminated due to initiation of a new clinical trial with an updated study design. | Other (stated, no rule matched) |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the… | Phase 2 | terminated | Oct 13, 2022 | Northwestern University | The study was closed due to accrual. | Enrollment / accrual |
| NCT06188208 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in… | Phase 1 | terminated | Jan 3, 2024 | Vividion Therapeutics, Inc. | The study has ended | Other (stated, no rule matched) |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | Phase 2 | terminated | Apr 6, 2015 | University of Pennsylvania | not stated | Not stated |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | Phase 1 / Phase 2 | terminated | Mar 7, 2019 | Genenta Science | LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for… | Safety / toxicity |
| NCT04674228 | Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 | — | terminated | Dec 19, 2020 | National Cancer Institute (NCI) | This particular part of the study could not be completed as endoscopy reports post completion of… | Other (stated, no rule matched) |
| NCT04745871 | Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in…(PREOP-PSMA) | N/A | terminated | Feb 9, 2021 | University Hospital, Brest | In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today,… | Other (stated, no rule matched) |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally… | Phase 2 | terminated | Aug 2, 2021 | NeoImmuneTech | sponsor decision (not for safety) | Safety / toxicity |
| NCT05744739 | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Feb 27, 2023 | Northwestern University | Premature withdrawal of investigational product per study sponsor. | Other (stated, no rule matched) |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence…(ROMECO) | N/A | withdrawn | Aug 15, 2023 | University Hospital, Tours | feasibility issue | Other (stated, no rule matched) |
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | Phase 2 | terminated | Dec 6, 2023 | Changhai Hospital | This investigator-initiated study closed to recruitment early due to slower-than-anticipated… | Investigator |
| NCT06505122 | Dyadic Life Review Intervention for Older Patients With Advanced Cancer) and Their…(DLR RCT) | N/A | terminated | Jul 17, 2024 | University of Rochester | This study is closing early to accrual as of 04/10/2026 due to lower than anticipated enrollment,… | Enrollment / accrual |
| NCT07340853 | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma | Phase 1 | suspended | Jan 14, 2026 | Thomas Martin, MD | Safety Review | Safety / toxicity |
| NCT04183699 | Optimizing the Number of Systematic COres During a MRI Target Biopsy | N/A | terminated | Dec 3, 2019 | IRCCS San Raffaele | The study was prematurely terminated due to recruitment challenges, insufficient enrollment,… | Enrollment / accrual |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in… | Phase 1 | withdrawn | Aug 5, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With… | Phase 2 | terminated | Aug 27, 2021 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study sponsor withdrew funding early, forcing this study to stop all activity and close… | Funding |
| NCT05929664 | Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell… | Phase 2 | suspended | Jul 3, 2023 | Thomas Jefferson University | Investigational product is not currently available to the study site. | Other (stated, no rule matched) |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in…(SKYSCRAPER-15) | Phase 3 | terminated | Feb 20, 2024 | Hoffmann-La Roche | Decision to terminate study was driven by results from preceding tiragolumab study… | Safety / toxicity |
| NCT03637335 | Comparing Palliative Radiotherapy With or Without Carboplatin(METAXIOM) | Phase 3 | terminated | Aug 20, 2018 | Institut Cancerologie de l'Ouest | The study was stopped due to insufficient recruitment. | Enrollment / accrual |
| NCT04906369 | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring | — | suspended | May 28, 2021 | Mayo Clinic | lack of funding | Funding |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT06348147 | Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell… | Phase 2 | withdrawn | Apr 4, 2024 | UNC Lineberger Comprehensive Cancer Center | budget | Funding |
| NCT07292285 | The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.(SNOWW) | — | withdrawn | Dec 18, 2025 | University of Colorado, Denver | Sponsor decided not to move forward with the site. | Sponsor / business decision |
| NCT07534813 | A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307)… | N/A | withdrawn | Apr 16, 2026 | Grit Biotechnology | Due to procedural adjustments at the investigative site, domestic registration on the China health… | Other (stated, no rule matched) |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT03598946 | Urinary Human Papilloma Virus Test in the General Population in Brittany(PapU-Access) | N/A | terminated | Jul 26, 2018 | University Hospital, Brest | unknwon | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 18, 2026source: clinicaltrials